Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 9,364 shares of the company's stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total transaction of $265,375.76. Following the sale, the insider now directly owns 84,762 shares of the company's stock, valued at $2,402,155.08. The trade was a 9.95 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Castle Biosciences Stock Up 2.1 %
Shares of CSTL opened at $27.09 on Friday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The firm has a market cap of $758.71 million, a P/E ratio of 135.46 and a beta of 0.92. The company's 50-day moving average price is $31.17 and its 200 day moving average price is $27.20. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.14. The business had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same period in the previous year, the firm earned ($0.26) EPS. On average, sell-side analysts forecast that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.
Wall Street Analyst Weigh In
AI breakthrough about to upend industry
From Porter & Company | Ad
Everyone is talking about AI right now.
The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI.
But here’s the thing.
I urge you to watch it now.
A number of research firms recently weighed in on CSTL. BTIG Research boosted their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Lake Street Capital boosted their price objective on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. KeyCorp boosted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Scotiabank raised their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, November 6th. Finally, Robert W. Baird lifted their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $39.71.
Read Our Latest Report on Castle Biosciences
Institutional Trading of Castle Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Castle Biosciences by 147.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company's stock worth $4,719,000 after buying an additional 98,571 shares during the period. Harbor Capital Advisors Inc. lifted its stake in Castle Biosciences by 11.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 153,907 shares of the company's stock worth $4,389,000 after acquiring an additional 15,200 shares in the last quarter. Lisanti Capital Growth LLC boosted its holdings in Castle Biosciences by 60.2% during the 3rd quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company's stock valued at $4,412,000 after acquiring an additional 58,160 shares during the period. Charles Schwab Investment Management Inc. grew its position in Castle Biosciences by 16.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company's stock valued at $7,836,000 after acquiring an additional 39,417 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Castle Biosciences during the third quarter worth about $1,478,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
